SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2/C2+ CORONARY IVL CATHETER
Shockwave Medical, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
The FDA record for P200039/S025 describes a 30-day notice submitted by Shockwave Medical, Inc. for the Shockwave intravascular lithotripsy system with the Shockwave C2/C2+ coronary IVL catheter. The stated change is a raw material impurity profile change in the hydrophilic coating at a supplier, listed under the reason process change involving a manufacturer, sterilizer, packager or supplier.
The identifier places S025 as a supplement to PMA P200039, so the notice concerns that previously cleared system rather than a new approval of the whole device. The record states only the reported purpose of the supplier coating-material change; it does not document safety or clinical effectiveness, and the notice does not specify which material, impurity, limit or test method is involved, nor the supplier's identity.
FDA approval order statement
a raw material impurity profile change (for the hydrophilic coating) at a supplier
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200039/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Shockwave intravascular lithotripsy system.
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200039 · Original PMA
Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter
P200039/S025 received
Application receipt date recorded by FDA.
P200039/S025 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P200039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Shockwave Medical, Inc. | PMA approval | Feb 12, 2021 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Shockwave Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5403 Betsy Ross Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P200039/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records